Journal
NATURE BIOTECHNOLOGY
Volume 38, Issue 12, Pages 1363-1365Publisher
NATURE RESEARCH
DOI: 10.1038/s41587-020-00757-8
Keywords
-
Categories
Ask authors/readers for more resources
The first antibody-drug conjugate to treat multiple myeloma can spur reversible loss of vision, but that may not be the case for other anti-BCMA T-cell therapies or bispecific antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
